http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-110607-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcce39a20bef16c3f04497659caba40f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 2017-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bca849eac16ad4f365cffa4954db3a16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b612e8a7b85bccf56d3e3aaf5ae7ab2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ec5b4e14de33dc72a3f14132f873b60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db56216d8fdad2c3d8cc40720d38d8aa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d09a97219061528e241c91f7c0fa6ad7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60895def9da9caf83b0046a77f998a4b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92d6007a3217d9e30936b98169a36563 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f020d7405292462eb7ef54c425b2cf8b |
| publicationDate | 2019-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-110607-A1 |
| titleOfInvention | ANTI-B7-H3 ANTIBODIES AND DRUG AND ANTIBODY CONJUGATES |
| abstract | Claim 1: An isolated antibody, or an antigen binding portion thereof, that binds to human B7-H3 (hB7-H3), characterized in that said antibody, or an antigen binding portion thereof, comprises a region heavy chain variable comprising a CDR3 having the amino acid sequence of SEQ ID No. 12 and a variable region of the light chain comprising a CDR3 having the amino acid sequence of SEQ ID No. 15. Claim 30: A anti-hB7-H3 antibody, or an antigen binding portion thereof, characterized in that it comprises a heavy chain CDR1 comprising an amino acid sequence illustrated in SEQ ID No. 10, a heavy chain CDR2 comprising a sequence of amino acids illustrated in SEQ ID No. 140, a heavy chain CDR3 comprising an amino acid sequence illustrated in SEQ ID No. 12, a light chain CDR1 comprising an illustrated amino acid sequence a in SEQ ID No. 136 or 138, a CDR2 of the light chain comprising an amino acid sequence illustrated in SEQ ID No. 7 and a CDR3 of the light chain comprising an amino acid sequence illustrated in SEQ ID No. 15. Claim 45: A pharmaceutical composition, characterized in that it comprises the anti-hB7-H3 antibody, or an antigen binding portion thereof, of any one of claims 1-44, and a pharmaceutically acceptable carrier. Claim 46: An anti-hB7-H3 (ADC) drug and antibody conjugate characterized in that it comprises an anti-hB7-H3 antibody of any one of claims 1-44 conjugated to a drug by means of a linker. Claim 114: A pharmaceutical composition characterized in that it comprises an effective amount of an ADC according to any one of claims 46-113, and a pharmaceutically acceptable carrier. Claim 124: A method of inhibiting or decreasing the growth of a solid tumor in a subject having a solid tumor, characterized in that said method comprises administering an effective amount of the ADCs of any of claims 46-114 to the subject having the tumor. solid, so that solid tumor growth is inhibited or decreased. Claim 135: A process for the preparation of an ADC according to structural formula (1): (DL-LK-) ₘ-Ab (1) wherein: D is the Bcl-xL inhibitor drug of formula (2a) , (2b), (2c), or (2d); L is the connector; Ab is an hB7-H3 antibody, where the hB7-H3 antibody comprises the heavy and light chain CDRs of huAb3v2.5, huAb3v2.6 or huAb13v1; LK represents a covalent connection that connects the L connector to the Ab antibody; and m is an integer between 1 and 20; characterized in that the process comprises: treating an antibody in an aqueous solution with an effective amount of a disulfide reducing agent at between 30 and 40 ° C for at least 15 minutes, and then cooling the antibody solution to between 20 and 27 ° C; add to the reduced antibody solution a water / dimethylsulfoxide solution comprising a tune selected from the group of 2.1 to 2176 (Table B); adjust the pH of the solution to a pH between 7.5 and 8.5; allow the reaction to progress between 48 and 80 hours to form the ADC; wherein the mass is displaced 18 ± 2 amu for each hydrolysis of a succinimide to a succinamide, measured by mass spectrometry with electroatomization; and wherein the ADC is optionally purified by hydrophobic interaction chromatography. |
| priorityDate | 2016-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.